Communiqués Alimera Sciences, Inc.

Actions

ALIM

US0162592028

Marché Fermé - Nasdaq Autres places de cotation 22:00:00 27/06/2024			Varia. 5j.	Varia. 1 janv.
5,53 ^USD	+0,18 %		+81,31 %	+28,01 %

24/06	Les plus fortes hausses de la mi-journée	MT
24/06	Mise à jour sectorielle : Les actions du secteur des soins de santé progressent avant le marché lundi	MT

Communiqués

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

ANI Pharmaceuticals to Acquire Alimera Sciences for $381 Million M&A Deal	27/06	AQ
Shareholder Alert: Ademi LLP investigates whether Alimera Sciences, Inc. has obtained a Fair Price for its Public Shareholders	24/06	PR
ALIM Alert: Monsey Firm of Wohl & Fruchter Investigating Fairness of the Sale of Alimera Sciences to ANI Pharmaceuticals	24/06	AQ
ALIM Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Alimera Sciences, Inc. Is Fair to Shareholders	24/06	BU
ANI Pharmaceuticals to Further Expand Rare Disease Business through Acquisition of Alimera Sciences	24/06	AQ
Alimera Sciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	04/06	AQ
Alimera Sciences: Q1 Earnings Snapshot	14/05	AQ
Alimera Sciences Reports First Quarter 2024 Results	14/05	AQ
Alimera Announces Scientific Data Highlighting YUTIQ® to be Presented at Upcoming Association for Research in Vision and Ophthalmology and Retina World Congress Conferences	07/05	AQ
Alimera Sciences to Report First Quarter 2024 Financial Results on May 14, 2024, and Provide Corporate Update	30/04	AQ
Alimera Sciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	20/03	AQ
Alimera Announces First Patient Randomized in Radiation Retinopathy Trial Being Conducted by the DRCR Retina Network	19/03	AQ
Alimera Sciences: Q4 Earnings Snapshot	07/03	AQ
Alimera Sciences Reports Fourth Quarter and Full Year 2023 Results	07/03	AQ
Alimera Sciences to Report Fourth Quarter and Full Year 2023 Financial Results on March 7, 2024, and Provide Corporate Update	29/02	AQ
The UK National Institute for Health and Care Excellence (NICE) Issues Final Draft Guidance to Provide Patients with a Natural Lens (Phakic Eye) Being Treated for Chronic Diabetic Macular Edema Access to ILUVIEN®	08/02	AQ
Alimera Completes Recruitment for the Synchronicity Study	04/01	AQ
Alimera Sciences Names Elliot Maltz as Chief Financial Officer and Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)	02/01	AQ
Alimera Sciences Appoints Todd Wood as President of U.S. Operations and Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)	12/12	AQ
Alimera Appoints Maggie A. Pax to Its Board of Directors	08/11	AQ

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Communiqués Alimera Sciences, Inc.

Actions

ALIM

US0162592028

Communiqués

Filtres